当前位置: 首页 > 详情页

Prevalence, risk factors, and management of asthma in China: a national cross-sectional study

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Resp & Pulm Circulat Disorders, Dept Pulm & Crit Care Med, Beijing, Peoples R China; [2]Capital Med Univ, Beijing Chao Yang Hosp, Dept Stomatol, Beijing, Peoples R China; [3]Capital Med Univ, Beijing Chao Yang Hosp, Dept Epidemiol, Beijing, Peoples R China; [4]Beijing Inst Resp Med, Beijing, Peoples R China; [5]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Beijing 100029, Peoples R China; [6]China Japan Friendship Hosp, Tobacco Med & Tobacco Cessat Ctr, Ctr Resp Med, Beijing, Peoples R China; [7]China Japan Friendship Hosp, Inst Clin Med Sci, Ctr Resp Med, Beijing, Peoples R China; [8]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China; [9]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China; [10]WHO Collaborating Ctr Tobacco Cessat & Resp Dis P, Beijing, Peoples R China; [11]Capital Med Univ, Dept Resp Med, Beijing, Peoples R China; [12]Shanxi Dayi Hosp, Dept Pulm & Crit Care Med, Taiyuan, Shanxi, Peoples R China; [13]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Xian, Shaanxi, Peoples R China; [14]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China; [15]Guizhou Prov Peoples Hosp, Dept Pulm & Crit Care Med, Guiyang, Guizhou, Peoples R China; [16]Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China; [17]China Med Univ, Hosp 1, Dept Pulm & Crit Care Med, Shenyang, Liaoning, Peoples R China; [18]Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Guangzhou Inst Resp Di, Guangzhou, Guangdong, Peoples R China; [19]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou, Zhejiang, Peoples R China; [20]Sichuan Univ, West China Hosp, State Key Lab Biotherapy China, Chengdu, Sichuan, Peoples R China; [21]Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China; [22]Peking Univ, Hosp 3, Dept Resp & Crit Care Med, Beijing, Peoples R China; [23]Beijing Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China; [24]Beijing Hosp, Natl Ctr Gerontol, Beijing, Peoples R China; [25]Chinese Acad Med Sci, Inst Basic Med Sci, Sch Basic Med, Peking Union Med Coll, Beijing, Peoples R China; [26]Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [27]Capital Med Univ, Beijing Childrens Hosp, Ctr Clin Epidemiol & Evidence Based Med, Natl Ctr Childrens Hlth, Beijing, Peoples R China; [28]Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England; [29]Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford, England; [30]Imperial Coll London, Natl Heart & Lung Inst, London, England; [31]Royal Brompton & Harefield NHS Trust, London, England; [32]Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; [33]Chinese Acad Med Sci, Beijing, Peoples R China; [34]Peking Union Med Coll, Beijing, Peoples R China
出处:
ISSN:

摘要:
Background Asthma is a common chronic airway disease worldwide. Despite its large population size, China has had no comprehensive study of the national prevalence, risk factors, and management of asthma. We therefore aimed to estimate the national prevalence of asthma in a representative sample of the Chinese population. Methods A representative sample of 57 779 adults aged 20 years or older was recruited for the national cross-sectional China Pulmonary Health (CPH) study using a multi-stage stratified sampling method with parameters derived from the 2010 census. Ten Chinese provinces, representative of all socioeconomic settings, from six geographical regions were selected, and all assessments were done in local health centres. Exclusion criteria were temporary residence, inability to take a spirometry test, hospital treatment of cardiovascular conditions or tuberculosis, and pregnancy and breastfeeding. Asthma was determined on the basis of a self-reported history of diagnosis by a physician or by wheezing symptoms in the preceding 12 months. All participants were assessed with a standard asthma questionnaire and were classed as having or not having airflow limitation through pulmonary function tests before and after the use of a bronchodilator (400 mu g of salbutamol). Risk factors for asthma were examined by multivariable-adjusted analyses done in all participants for whom data on the variables of interest were available. Disease management was assessed by the self-reported history of physician diagnosis, treatments, and hospital visits in people with asthma. Findings Between June 22, 2012, and May 25, 2015, 57 779 participants were recruited into the CPH study. 50 991 (21 446 men and 29 545 women) completed the questionnaire survey and had reliable post-bronchodilator pulmonary function test results and were thus included in the final analysis. The overall prevalence of asthma in our sample was 4.2% (95% CI 3.1-5.6), representing 45.7 million Chinese adults. The prevalence of asthma with airflow limitation was 1.1% (0.9-1.4), representing 13.1 million adults. Cigarette smoking (odds ratio [OR] 1.89, 95% CI 1.26-2.84; p=0.004), allergic rhinitis (3.06, 2.26-4.15; p<0.0001), childhood pneumonia or bronchitis (2.43, 1.44-4.10; p=0.002), parental history of respiratory disease (1.44, 1.02-2.04; p=0.040), and low education attainment (p=0.045) were associated with prevalent asthma. In 2032 people with asthma, only 28.8% (95% CI 19.7-40.0) reported ever being diagnosed by a physician, 23.4% (13.9-36.6) had a previous pulmonary function test, and 5.6% (3.1-9.9) had been treated with inhaled corticosteroids. Furthermore, 15.5% (11.4-20.8) people with asthma reported at least one emergency room visit and 7.2% (4.9-10.5) at least one hospital admission due to exacerbation of respiratory symptoms within the preceding year. Interpretation Asthma is prevalent but largely undiagnosed and undertreated in China. It is crucial to increase the awareness of asthma and disseminate standardised treatment in clinical settings to reduce the disease burden. Copyright (C) 2019 Elsevier Ltd. All rights reserved.

基金:
语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
JCR分区:
出版当年[2017]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Resp & Pulm Circulat Disorders, Dept Pulm & Crit Care Med, Beijing, Peoples R China; [4]Beijing Inst Resp Med, Beijing, Peoples R China;
通讯作者:
通讯机构: [5]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Beijing 100029, Peoples R China; [8]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China; [9]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China; [10]WHO Collaborating Ctr Tobacco Cessat & Resp Dis P, Beijing, Peoples R China; [11]Capital Med Univ, Dept Resp Med, Beijing, Peoples R China; [33]Chinese Acad Med Sci, Beijing, Peoples R China; [34]Peking Union Med Coll, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院